SillaJen and Lee's Pharma to initiate Phase III liver cancer trial of Pexa-Vec

South Korean biotherapeutics firm SillaJen and Hong Kong-based biopharmaceutical company Lee's Pharmaceutical Holdings have secured approval from the China Food and Drug Administration (CFDA) for a Phase III clinical trial (PHOCUS) of Pexa-Vec in pat …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news